Table 1.
Baseline Characteristics by Treatment Group*
| MMF | Placebo | |
|---|---|---|
| Number of Subjects Randomized† | 39 | 19 |
| # (%) Female | 33 (85%) | 15 (79%) |
| Mean ± s.d. Age | 51.3 ± 10.3 | 51.8 ± 11.6 |
| Race | ||
| # (%) White/Caucasian | 35 (90%) | 17 (89%) |
| # (%) Black/African-American | 1 (3%) | 1 (5%) |
| # (%) Multi-race, Asian, Other | 3 (8%) | 1 (5%) |
| # (%) Ever Diagnosed with IC/PBS | 38 (97%) | 19 (100%) |
| Mean ± s.d. Years Since Diagnosis (if applicable) | 6.4 ± 4.1 | 6.3 ± 5.9 |
| Mean ± s.d. Years Since Onset of Initial Symptoms | 13.8 ± 12.0 | 14.4 ± 14.4 |
| Mean ± s.d. Pain Score (0–10) | 6.9 +/− 1.5 | 7.2 +/− 1.2 |
| Mean ± s.d. Urgency Score (0–10) | 7.1 +/− 1.8 | 7.1 +/− 1.7 |
| Mean ± s.d. Frequency Score (0–10) | 7.7 +/− 1.4 | 7.4 +/− 1.8 |
| Mean ± s.d. IC Symptom Index | 15.7 +/− 3 | 15.1 +/− 3 |
| Mean ± s.d. IC Problem Index | 12.9 +/− 3 | 12.8 +/− 3 |
| Mean ± s.d. SF-12 PCS (38,18) | 34.9 +/− 10 | 34.8 +/− 11 |
| Mean ± s.d. SF-12 MCS (38,18) | 42.6 +/− 11 | 38.3 +/− 13 |
| Mean ± s.d. FSFI total (30,12) | 14.0 +/− 10 | 11.5 +/− 9 |
| Mean ± s.d. McGill total (37,16) | 21.5 +/− 10.4 | 21.5 +/− 11.3 |
*
For the symptom scores shown, the measurements at the two baseline visits were averaged to give the overall baseline score.
†
Approximately nine subjects on each arm were missing data on voiding frequency, and eight subjects on each arm were missing data on years since symptoms began. At most one subject was missing data for all other measures.